Ibrutinib: Indication of added benefit in one of three therapeutic indications
Monday, May 2, 2016 - 11:50
in Health & Medicine
No added benefit has been proven for chronic lymphocytic leukaemia and Waldenström macroglobulinaemia. Certain patients with relapsed or refractory mantle cell lymphoma benefit from the drug.